General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-22 | 2024-03 | 0 | N/A | N/A | N/A |
2024-04-03 | 2023-12 | -0.25 | N/A | N/A | N/A |
2023-11-14 | 2023-09 | -0.36 | -0.39 | -0.03 | -8.33% |
2023-11-14 | 2023-09 | -0.36 | N/A | N/A | N/A |
2023-08-10 | 2023-06 | -0.56 | -0.49 | 0.07 | 12.50% |
2023-08-10 | 2023-06 | -0.56 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-13 | Wedbush | Downgrade | Outperform | Neutral |
2023-08-10 | Stifel | Downgrade | Buy | Hold |
2023-08-10 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2023-06-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-10 | Stifel | Upgrade | Buy | Buy |
2023-05-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-10-18 | BAKER BROS ADVISORS L.P. | Unknown | 0.00 | Sale |
2020-02-24 | CAVET GUY LAWRENCE | Chief Technology Officer | 87.76K | Sale |
2023-08-31 | COURTNEY PHILLIPS | General Counsel | 50.43K | Sale |
2023-08-01 | CROSS HERBERT C | Chief Financial Officer | 72.82K | Sale |
2023-08-01 | GOULD STEPHEN E PH.D. | Officer | 28.42K | Sale |
2021-03-16 | GREENBERG NORMAN MICHAEL | Officer | 0.00 | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baker Brothers Advisors, LLC | 3.53M | 3.46M | 10.84% |
2023-06-29 | Boxer Capital, LLC | 2.20M | 2.16M | 6.76% |
2023-06-29 | Vanguard Group Inc | 1.33M | 1.30M | 4.08% |
2023-06-29 | Blackrock Inc. | 1.19M | 1.17M | 3.66% |
2023-06-29 | Bill & Melinda Gates Foundation | 931.82K | 913.18K | 2.86% |
2023-06-29 | ExodusPoint Capital Management, LP | 466.83K | 457.49K | 1.43% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 905.47K | 887.36K | 2.78% |
2023-06-29 | Vanguard Extended Market Index Fund | 393.23K | 385.36K | 1.21% |
2023-05-30 | Fidelity Extended Market Index Fund | 148.88K | 148.88K | 0.46% |
2023-06-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 150.00K | 147.00K | 0.46% |
2023-06-29 | Fidelity Small Cap Enhanced Index Fund | 71.25K | 69.83K | 0.22% |
2023-08-30 | iShares Micro Cap ETF | 64.81K | 23.89K | 0.20% |
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
Added 300 Fuk the shorts
Don’t let the shorts steal your shares
Added more Monday we gap up!!
Bought more at $5
I’m holding a 6.15 bag
Added 500 here let’s go